Sirtex Medical Limit
SRX
End-of-day quote AUSTRALIAN SECURITIES EXCHANGE LIMITED - 09/13
33.55AUD
+0.09%
Prev.33.5200
Open33.5200
High33.5800
Low33.5100
Volume619 777
Financials
Sales 2019 242 M
EBIT 2019 75,1 M
R. net 2019 55,7 M
Tréso. 2019 128 M
Rend. 2019 0,83%
P/E ratio 2019 34,59
P/E ratio 2020 33,89
EV / Sales 2019 7,30x
EV / Sales 2020 7,14x
Capitalization 1 894 M
Company
Sirtex Medical Ltd. engages in the research, commercial development, manufacture, and distribution of liver cancer treatments.It offers targeted radiation therapy known as SIR-Spheres Y-90 resin microspheres.Its clinical programs include SIRFLOX, FOXFIRE/FOXFIRE Global, SARAH, SIRveNIB, and SORAMIC.
Sector :
Biotechnology & Medical Research - NEC
Calendar :
2019-02-20 Earnings Release
Trading Rating :
Investor Rating :
Latest news
08/24SIRTEX MEDICAL LIMITED : annual earnings release
07/05CHINA GRAND PHA AND HEALTHCARE HLD : Pharm (512) to raise HK$2.88bn from rights issue
AQ
06/20GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET GROWTH ANALYSIS, SHARE, DEMAND BY REGIONS, TYPES AND ANALYSIS OF KEY PLAYERS- RESEARCH FORECASTS TO 2023 : The research provide Industry Overview, Market history, Market competition, Development and Trades and Trade policies. The research provide investment analysis opportunities market shares profiling top key players Novartis International AG (Sandoz), Pharmascience Inc., Omega Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Mylan NV, Ipsen
AQ
06/16CHINA GRAND PHA AND HEALTHCARE HLD : Pharm & partner to buy Sirtex at AUD1.9bn
AQ
05/23China Grand Pharm may participate in Sirtex Medical buy
AQ
05/07VARIAN MEDICAL : Notes Receipt of Competing Bid by Sirtex
AQ
05/04Chinese firm makes last-minute $1.4 billion offer for Australia's Sirtex, trumps Varian
RE
02/16SIRTEX MEDICAL LIMITED : half-yearly earnings release
Technical analysis trends
Short TermMid-TermLong Term
TrendBullishBullishBullish
Resistance33,635,240,1
Spread/Res.-0,06%-4,7%-16%
Spread/Supp.4,3%10%53%
Support32,230,521,9